Tatsiana Castor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tatsiana Castor has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Katrin Rohlfing
Department of Cardiology and Angiology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany
2 shared publications - Meinrad Gawaz
Department of Cardiology and Angiology, University Hospital Tübingen, University Tübingen, Tübingen, Germany
2 shared publications - Ravi Hochuli
Department of Cardiology and Angiology University Hospital Tübingen, University Tübingen Tübingen Germany
2 shared publications - Zoi Laspa
Department of Cardiology and Angiology University Hospital Tübingen, University Tübingen Tübingen Germany
2 shared publications - Aylin Balmes
Institute of Applied Physics, University of Tübingen, Auf der Morgenstelle 10, 72076 Tübingen, Germany
1 shared publication - David Schaale
Department of Cardiology and Angiology, University Hospital Tübingen, Eberhard Karls University Tübingen , Otfried-Müller-Str. 10, Tübingen 72076
1 shared publication
Latest Publications
- Open Access
- 12 January 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (2) , e71463
Receptor‐Dependent and ‐Independent Effects of Hemin on Platelet Plasma Membrane Disintegration
Microhemorrhages are an underestimated aspect in the pathophysiology of vulnerable plaques and aneurysms. Erythrocyte liberation within hemorrhages leads to extracellular hemoglobin accumulation and iron‐containing hemin generation. Hemin induces platelet activation, thrombosis, and ferroptosis‐mediated destruction of platelet membranes through GPVI/CLEC‐2 signaling. Hemin‐toxicity results in destruction of platelet membranes, which is caused by ferroptosis, a non‐apoptotic cell death. Antiplatelet drugs have limited effect on hemin‐induced activation. We evaluated the effect of hemin on platelet function using light transmission aggregometry and multipanel flow cytometry. We found that P2Y 12 and COX‐1 inhibition attenuates hemin‐induced aggregation only at low hemin concentrations (3.1/6.25 μM), whereas at higher concentrations (12.5/25 μM) no substantial inhibition was found. High hemin concentrations enhance phosphatidylserine exposure, procoagulant and microvesicle formation as well as ferroptosis, which was not attenuated in the presence of Src‐inhibitors, indicating that membrane‐disintegration is not primarily mediated via GPVI/CLEC‐2 receptor‐dependent ITAM‐signaling. In contrast, iron chelation by deferoxamine significantly reduced microvesicle and ROS generation, loss of mitochondrial membrane potential and lipid peroxidation. Soluble recombinant Fc‐GPVI scavenging of hemin protects against hemin‐induced platelet activation, plasma membrane disintegration and microvesicle formation. High hemin concentrations lead to plasma membrane disintegration and ferroptosis, inhibited by iron chelation and hemin scavenging via soluble Fc‐GPVI, but not by GPVI/CLEC‐2 receptor‐mediated ITAM signaling. We speculate that iron overload enables receptor‐independent ferroptosis induction by hemin and may represent a therapeutic target to prevent platelet‐driven thrombosis in microhemorrhages.
- 12 January 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (2) , e71463
Open AccessReceptor‐Dependent and ‐Independent Effects of Hemin on Platelet Plasma Membrane Disintegration
Microhemorrhages are an underestimated aspect in the pathophysiology of vulnerable plaques and aneurysms. Erythrocyte liberation within hemorrhages leads to extracellular hemoglobin accumulation and iron‐containing hemin generation. Hemin induces platelet activation, thrombosis, and ferroptosis‐mediated destruction of platelet membranes through GPVI/CLEC‐2 signaling. Hemin‐toxicity results in destruction of platelet membranes, which is caused by ferroptosis, a non‐apoptotic cell death. Antiplatelet drugs have limited effect on hemin‐induced activation. We evaluated the effect of hemin on platelet function using light transmission aggregometry and multipanel flow cytometry. We found that P2Y 12 and COX‐1 inhibition attenuates hemin‐induced aggregation only at low hemin concentrations (3.1/6.25 μM), whereas at higher concentrations (12.5/25 μM) no substantial inhibition was found. High hemin concentrations enhance phosphatidylserine exposure, procoagulant and microvesicle formation as well as ferroptosis, which was not attenuated in the presence of Src‐inhibitors, indicating that membrane‐disintegration is not primarily mediated via GPVI/CLEC‐2 receptor‐dependent ITAM‐signaling. In contrast, iron chelation by deferoxamine significantly reduced microvesicle and ROS generation, loss of mitochondrial membrane potential and lipid peroxidation. Soluble recombinant Fc‐GPVI scavenging of hemin protects against hemin‐induced platelet activation, plasma membrane disintegration and microvesicle formation. High hemin concentrations lead to plasma membrane disintegration and ferroptosis, inhibited by iron chelation and hemin scavenging via soluble Fc‐GPVI, but not by GPVI/CLEC‐2 receptor‐mediated ITAM signaling. We speculate that iron overload enables receptor‐independent ferroptosis induction by hemin and may represent a therapeutic target to prevent platelet‐driven thrombosis in microhemorrhages.
- Open Access
- 12 November 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (21) , e70155
Hemin promotes platelet activation and plasma membrane disintegration regulated by the subtilisin‐like proprotein convertase furin
Platelet activation plays a critical role in thrombosis and hemostasis. Several pathophysiological situations lead to hemolysis, resulting in the liberation of free ferric iron‐containing hemin. Hemin has been shown to activate platelets and induce thrombo‐inflammation. Classical antiplatelet therapy failed to prevent hemin‐induced platelet activation. Thus, the aim of the present study was to characterize the mechanism of hemin‐induced platelet death (ferroptosis). We evaluated the in vitro effect of hemin on platelet activation, signaling, oxylipins, and plasma membrane destruction using light transmission aggregometry, ex vivo thrombus formation, multiparametric flow cytometry, micro‐UHPLC mass spectrometry for oxylipin profiling, and scanning ion conductance microscopy (SICM). We found that hemin induces platelet cell death indicated by increased ROS levels, phosphatidyl serine (PS) exposure, and loss of mitochondrial membrane potential (ΔΨm). Further, hemin causes lipid peroxidation and generation of distinct oxylipins, which strongly affects plasma membrane integrity leading to generation of platelet‐derived microvesicles. Interestingly, hemin‐dependent platelet death (ferroptosis) is specifically regulated by the subtilisin‐like proprotein convertase furin. In summary, platelet undergo a non‐apoptotic cell death mediated by furin. Inhibition of furin may offer a therapeutic strategy to control hemin‐induced thrombosis and thrombo‐inflammation at a site of hemolysis.
- 12 November 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (21) , e70155
Open AccessHemin promotes platelet activation and plasma membrane disintegration regulated by the subtilisin‐like proprotein convertase furin
Platelet activation plays a critical role in thrombosis and hemostasis. Several pathophysiological situations lead to hemolysis, resulting in the liberation of free ferric iron‐containing hemin. Hemin has been shown to activate platelets and induce thrombo‐inflammation. Classical antiplatelet therapy failed to prevent hemin‐induced platelet activation. Thus, the aim of the present study was to characterize the mechanism of hemin‐induced platelet death (ferroptosis). We evaluated the in vitro effect of hemin on platelet activation, signaling, oxylipins, and plasma membrane destruction using light transmission aggregometry, ex vivo thrombus formation, multiparametric flow cytometry, micro‐UHPLC mass spectrometry for oxylipin profiling, and scanning ion conductance microscopy (SICM). We found that hemin induces platelet cell death indicated by increased ROS levels, phosphatidyl serine (PS) exposure, and loss of mitochondrial membrane potential (ΔΨm). Further, hemin causes lipid peroxidation and generation of distinct oxylipins, which strongly affects plasma membrane integrity leading to generation of platelet‐derived microvesicles. Interestingly, hemin‐dependent platelet death (ferroptosis) is specifically regulated by the subtilisin‐like proprotein convertase furin. In summary, platelet undergo a non‐apoptotic cell death mediated by furin. Inhibition of furin may offer a therapeutic strategy to control hemin‐induced thrombosis and thrombo‐inflammation at a site of hemolysis.